Expansion in DNA Research Is Driving Strong Demand for Life Science Space in the United States

/in , /by

A growing seniors population and increasing prevalence of high-cost diseases like diabetes has generated a surge in funding for healthcare research in recent years and, along with it, demand for life science-biotech lab space.

But the biggest impact on demand for wet lab space has resulted from mapping of the complete human genome and subsequent advances in biotechnology, according to Ian Anderson, director of research and analysis with real estate services firm CBRE. Anderson notes that the price for sequencing a human genome has dropped from $100,000 to just $1,000, resulting in massive expansion in DNA research and development of new biotech tools, like the CRISPR gene editing system.

“This ‘gold rush’ of information is providing the pharma industry the ability to tailor treatments to individuals and actually cure diseases, not just diagnose them and treat symptoms,” Anderson says.

As a result, lab space vacancy in the top three life science markets—Boston, the San Francisco Bay Area and San Diego—averaged between 4.0 and 6.0 percent at the end of 2017, the most recent period for which data is available, according a report from real estate services firm CBRE. In certain submarkets, including the Bay Area’s Peninsular and Emeryville/Berkley markets, Cambridge, Mass. and San Diego’s Torrey Pines, vacancy ranged between 0 and about 2.5 percent, respectively.

With ongoing high demand, vacancy and upward rent momentum have strengthen even further since the report was released, according to Anderson.

Tight vacancy is generating new construction in the San Francisco Bay Area and Boston-Cambridge markets, as well as growing life science markets, including Chicago and the Raleigh-Durham Research Triangle. San Diego is seeing significant new construction too, as well as redevelopment of office and industrial buildings for life science and biotech research and development.

These three markets have received the lion’s share funding from both the National Institutes of Health (NIH) and venture capital (VC) firms. According to the California Life Sciences Association, the state’s life science and biotech companies were awarded $3.8 billion in NIH grants in 2017 and attracted $6.7 billion in VC investment. The Massachusetts Biotechnology Council reported that Massachusetts life science and biotech companies were awarded $2.7 billion in NIH grants in 2017 and attracted $3.6 billion in VC investment.

“The life science sector is seeing record levels of IPO and funding activity,” says Greg Bisconti, Cushman & Wakefield executive director who heads the company’s life science practice nationally. A third quarter 2018 Cushman & Wakefield report notes that fundraising, IP, and merger and acquisition (M&A) activity are at an all-time, with Big Pharma playing a significant role in M&A and driving significant growth in all major biotech hubs.

The boom in funding has ratcheted up competition for talent and facilities, setting off a “war for talent” among life sciences companies, notes Bisconti.

“There’s a lot of hiring and organic growth of companies, but every company is limited by talent available,” he says. “When building and growing a life sciences company, key talent is being selective about the job opportunity and their future workplace, which highlights that companies need to secure quality space in which to grow talent.”

More patents are coming out of the New York life science cluster than San Francisco and Boston combined, according to John H. Cunningham, executive vice president and New York City regional market director at Alexandria Real Estate Equities. With both U.S. and European life science companies establishing beachheads in the city, Alexandria recently announced plans for expansion of the life science cluster, which is located on 3.5 acres in Manhattan’s Eastside Medical Corridor near New York University’s academic medical center and Bellevue Hospital. The company also acquired two nearby properties that will be redeveloped for its life science and biotech tenants.

The addition of the 550,000-sq.-ft. North Tower will bring total space at the Alexandria Center to approximately 1.3 million sq. ft. The building will provide collaborative space for scientists, as well as start-up space.

The company also acquired the 593,000-sq.-ft. Pfizer building at 219 East 42nd St. and a 177,000-sq.-ft. industrial building in Long Island City, both of which will be redeveloped. “We’re building an ecosystem that will allow growing companies to remain within our platform. People want to stay here with peers because it helps them grow and flourish,” says Cunningham.

CBRE’s Anderson notes that Los Angeles is producing a lot of STEM talent as well, and there is building momentum for a cluster around Harbor-UCLA Medical Center in the South Bay-Torrance area and life science and biotech companies located around UCLA and in the San Fernando Valley and Thousand Oaks areas. For now, however, many life science and biotech tenants want to be close to where collaboration and scientific breakthroughs are happening (San Francisco Bay Area, Boston-Cambridge or San Diego), Anderson notes.

 

Source:  NREI

New Facilities, Partnerships Help Healthcare Systems Grow

/in , /by

As more people move into metro Denver’s northwest corridor, Boulder Community Health will form partnerships and expand its services in areas where the community is growing.

Boulder Community Health, a not-for-profit healthcare organization established in 1922, has two hospitals and about 20 primary care practices in Boulder County, said Chief Strategy Officer and Vice President of Business Development Dr. Paul Hinchey, a panelist for Bisnow’s State of Denver Healthcare event Oct. 4. BCH is also invested in urgent- and specialty-care facilities and has one free-standing emergency department.

“We’re a big, little community hospital,” Hinchey said. “We’re a fixture in the community.”

And BCH, which is supported by the Boulder Community Health Foundation, continues to add services to its network, whether through partnerships or building new facilities.

“No one shrinks to greatness,” Hinchey said. “Growth has to be part of the strategy … Everyone is focused on cost savings, but the other piece is that you have to grow strategically if you’re going to stay alive.”

In 2015, BCH sold an older hospital on 9 acres along Broadway at Alpine and Balsam avenues to the city of Boulder for $40M. The sale enabled it to build the new 180-bed Foothills Hospital at 4747 Arapahoe Ave., and the city allowed BCH to continue to lease back its existing facilities  on the site until its new ones were completed. BCH will be off the old campus by March.

Much of BCH’s expansion has been to the east of Boulder because that is where the population is shifting, Hinchey said. It is building new facilities in Erie and Superior.

“None of the young folks can afford to live in Boulder so they’re living out east,” Hinchey said. “We’re expanding typically more to the east. It’s a strategic capture of market share. If they don’t need to come into the hospital, it’s nice to be able to access their care closer to home.”

BCH is continuously evaluating its service lines to ensure it maintains a strong relationship with the community. If it can’t be the No. 1 or No. 2 provider of a particular service, it will try to partner with the organization that can, Hinchey said. For example, it is working with the University of Colorado-Boulder to establish an inpatient rehabilitation program.

“They have one on their main campus, but they’re saturated in terms of volume and were looking to expand,” Hinchey said. “We were looking for a partner. Everyone is getting a little more cautious right now about getting overextended. The big players are starting to think it is better to find a partner to work with on something than to jump in and take it on all by yourself.”

When it comes to building new facilities, Children’s Hospital Colorado takes a similar approach to BCH by clustering additional services around its hospitals. Children’s, which has about 16 locations throughout the region, is building a free-standing hospital at C-470 and Lucent Boulevard in Littleton. The site wasn’t able to accommodate all of its outpatient clinics, so it is looking at another location about a mile away, said Children’s Hospital Colorado Director of Facilities Operations Network of Care Henry Biela, another panelist for the Bisnow healthcare event.

Children’s also is looking at expanding its dental and outpatient clinics in a building near the Anschutz Medical Campus, where its main hospital is.

“We look for locations that are in proximity to another major hub of ours that are still close enough to those individuals who were going to our original location,” Biela said.

 

Source:  Bisnow

MSM, Carter Break Ground On $52M Mixed-Use Project In Atlanta

/in , , , /by

Morehouse School of Medicine (MSM) and Carter, an Atlanta-based developer, have broken ground for the first phase of Lee Street Campus, a $52 million mixed-use development in Atlanta’s Historic West End.

The $52 million development will include MSM’s first on-campus graduate student housing, offering 187 units in a mix of studio, one- and two-bedroom layouts; a 25,000-square-foot ambulatory health facility; 9,000-square-foot fitness/wellness center; 2,500 square feet of retail space; and a four-level parking deck at the corner of Lee Street and Westview Drive.

The ownership joint venture for the project includes equity investments by MSM, Carter and Campus Life Fund, sponsored by Atlantic American Partners. Patterson Real Estate Advisors Group secured construction financing, which was provided by First Citizens Bank.

 

Source:  RE Business